Primary Sclerosing Cholangitis
On this page:
- What is primary sclerosing cholangitis (PSC)?
- What causes PSC?
- Who gets PSC?
- What are the symptoms of PSC?
- What are the complications of PSC?
- How is PSC diagnosed?
- How is PSC treated?
- Points to Remember
- Hope through Research
- For More Information
What is primary sclerosing cholangitis (PSC)?
PSC is a disease that damages and blocks bile ducts inside and outside the liver. Bile is a liquid made in the liver. Bile ducts are tubes that carry bile out of the liver to the gallbladder and small intestine. In the intestine, bile helps break down fat in food.
In PSC, inflammation of the bile ducts leads to scar formation and narrowing of the ducts over time. As scarring increases, the ducts become blocked. As a result, bile builds up in the liver and damages liver cells. Eventually, scar tissue can spread throughout the liver, causing cirrhosis and liver failure.
What causes PSC?
The causes of PSC are not known. Genes, immune system problems, bacteria, and viruses may play roles in the development of the disease.
PSC is linked to inflammatory bowel disease (IBD). About three out of four people with PSC have a type of IBD called ulcerative colitis. The link between PSC and IBD is not yet understood.
Who gets PSC?
Most people with PSC are adults but the disease also occurs in children. The average age at diagnosis is 40. PSC is more common in men than women. Having family members with PSC may increase a person's risk for developing PSC.
What are the symptoms of PSC?
The main symptoms of PSC are itching, fatigue, and yellowing of the skin or whites of the eyes. An infection in the bile ducts can cause chills and fever. PSC progresses slowly, so a person can have the disease for years before symptoms develop.
What are the complications of PSC?
PSC can lead to various complications, including
- deficiencies of vitamins A, D, E, and K
- infections of the bile ducts
- cirrhosis—extensive scarring of the liver
- liver failure
- bile duct cancer
How is PSC diagnosed?
Blood tests to check levels of liver enzymes are the first step in diagnosing PSC. Doctors confirm the diagnosis using cholangiography, which provides pictures of the bile ducts.
Cholangiography can be performed in the following ways:
Endoscopic retrograde cholangiopancreatography (ERCP). ERCP uses an endoscope—a long, flexible, lighted tube—that goes down the mouth, beyond the stomach, and into the duodenum to reach an area in the digestive tract where dye can be injected into the bile ducts. X rays are taken when the dye is injected. ERCP also can be used to take a tissue sample or to treat blocked ducts. More information about ERCP is in the National Digestive Diseases Information Clearinghouse's fact sheet ERCP (Endoscopic Retrograde Cholangiopancreatography), available at www.digestive.niddk.nih.gov or by calling 1–800–891–5389.
Percutaneous transhepatic cholangiography. This procedure involves inserting a needle through the skin and placing a thin tube into a duct in the liver. Dye is injected through the tube and x rays are taken.
Magnetic resonance cholangiopancreatography (MRCP). MRCP uses magnetic resonance imaging (MRI) to obtain pictures of the bile ducts. MRI machines use radio waves and magnets to scan internal organs and tissues. MRCP does not involve using x rays or inserting instruments into the body. This safe and painless test is increasingly used for diagnosis.
Other testing may include ultrasound exams and a liver biopsy. Ultrasound uses sound waves to create images of organs inside the body. A biopsy involves removal of a small piece of tissue for examination with a microscope.
How is PSC treated?
Although researchers have studied many treatments, none has been shown to cure or slow the progress of PSC. Treatment of PSC aims to relieve symptoms and manage complications. Medical treatment may include various medications to relieve itching, antibiotics to treat infections, and vitamin supplements. Instruments passed through an endoscope during ERCP can help open blocked bile ducts.
Liver transplantation may be an option if the liver begins to fail.
Points to Remember
- Primary sclerosing cholangitis (PSC) inflames, scars, and blocks bile ducts inside and outside the liver.
- When bile ducts become blocked, bile builds up in the liver and damages liver cells.
- PSC can lead to vitamin deficiencies, infections, bile duct cancer, cirrhosis, liver failure, and the need for a liver transplant.
- The cause of PSC is not known.
- Many people with PSC also have ulcerative colitis, an inflammatory bowel disease.
- Treatment includes medications to treat symptoms and complications of PSC.
Hope through Research
The National Institute of Diabetes and Digestive and Kidney Diseases conducts and supports research related to digestive diseases, including PSC. A complete listing of clinical research studies, including those related to PSC, can be found at www.ClinicalTrials.gov.
For More Information
American Liver Foundation
75 Maiden Lane, Suite 603
New York, NY 10038–4810
Phone: 1–800–GO–LIVER (465–4837) or 212–668–1000
National Digestive Diseases Information Clearinghouse
The National Digestive Diseases Information Clearinghouse (NDDIC) is a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK is part of the National Institutes of Health of the U.S. Department of Health and Human Services. Established in 1980, the Clearinghouse provides information about digestive diseases to people with digestive disorders and to their families, health care professionals, and the public. The NDDIC answers inquiries, develops and distributes publications, and works closely with professional and patient organizations and Government agencies to coordinate resources about digestive diseases.
Publications produced by the Clearinghouse are carefully reviewed by both NIDDK scientists and outside experts. This publication was reviewed by Keith D. Lindor, M.D., Mayo Clinic, Rochester, MN.
This publication is not copyrighted. The Clearinghouse encourages users of this publication to duplicate and distribute as many copies as desired.
NIH Publication No. 08–4626
Page last updated April 30, 2012